ES2712052T3 - Métodos para reducir partículas de LDL pequeñas y densas - Google Patents
Métodos para reducir partículas de LDL pequeñas y densas Download PDFInfo
- Publication number
- ES2712052T3 ES2712052T3 ES09821200T ES09821200T ES2712052T3 ES 2712052 T3 ES2712052 T3 ES 2712052T3 ES 09821200 T ES09821200 T ES 09821200T ES 09821200 T ES09821200 T ES 09821200T ES 2712052 T3 ES2712052 T3 ES 2712052T3
- Authority
- ES
- Spain
- Prior art keywords
- ldl
- compound
- pattern
- particle size
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 Cc(cc(cc1)SC[C@](*)COc2ccc(C(F)(F)F)cc2)c1OCC(O)=O Chemical compound Cc(cc(cc1)SC[C@](*)COc2ccc(C(F)(F)F)cc2)c1OCC(O)=O 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10648308P | 2008-10-17 | 2008-10-17 | |
| PCT/US2009/060679 WO2010045361A1 (en) | 2008-10-17 | 2009-10-14 | Methods of reducing small, dense ldl particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2712052T3 true ES2712052T3 (es) | 2019-05-09 |
Family
ID=42106878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09821200T Active ES2712052T3 (es) | 2008-10-17 | 2009-10-14 | Métodos para reducir partículas de LDL pequeñas y densas |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20100152295A1 (enExample) |
| EP (1) | EP2346498B1 (enExample) |
| JP (1) | JP5694941B2 (enExample) |
| KR (1) | KR20110091680A (enExample) |
| CN (1) | CN102209532B (enExample) |
| BR (1) | BRPI0920170A2 (enExample) |
| CA (1) | CA2740874C (enExample) |
| ES (1) | ES2712052T3 (enExample) |
| MX (1) | MX2011004077A (enExample) |
| TW (1) | TWI491392B (enExample) |
| WO (1) | WO2010045361A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130273154A1 (en) * | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
| KR20200006177A (ko) | 2011-03-02 | 2020-01-17 | 제롬 쉔타그 | 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단 |
| MX2016006583A (es) * | 2013-11-20 | 2016-09-06 | Cymabay Therapeutics Inc | Tratamiento de hipercolesterolemia familiar homocigotica. |
| UA120756C2 (uk) | 2014-03-20 | 2020-02-10 | Сімабей Терапьютікс, Інк. | Лікування внутрішньопечінкових холестатичних захворювань |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| WO2015157697A1 (en) | 2014-04-11 | 2015-10-15 | Cymabay Therapeutics, Inc. | Treatment of nafld and nash |
| PT3522880T (pt) * | 2016-10-05 | 2021-02-22 | Mitobridge Inc | Métodos de tratamento de lesão renal aguda |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI802783A7 (fi) | 1979-09-05 | 1981-01-01 | Glaxo Group Ltd | Fenolijohdoksia. |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| US7576131B2 (en) | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| JP2001354671A (ja) | 2000-04-14 | 2001-12-25 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
| WO2002014291A1 (fr) | 2000-08-11 | 2002-02-21 | Nippon Chemiphar Co.,Ltd. | ACTIVATEURS DE PPAR$G(d) |
| JPWO2002046154A1 (ja) | 2000-12-05 | 2004-04-08 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
| GB0031109D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| WO2002100351A2 (en) | 2001-06-11 | 2002-12-19 | Merck & Co., Inc. | A method for treating inflammatory diseases by administering a ppar-delta agonist |
| GB0121436D0 (en) * | 2001-09-04 | 2001-10-24 | Pfizer Ltd | Biomodulated multiparticulate formulations |
| WO2004092117A1 (en) * | 2003-04-07 | 2004-10-28 | Kalypsys, Inc. | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
| US20070037882A1 (en) | 2003-04-22 | 2007-02-15 | Astellas Pharma Inc. | Remedy for cerebral neurodegenerative diseases using ppar agonist |
| US7199259B2 (en) | 2003-06-20 | 2007-04-03 | Metabolex, Inc. | Resolution of α-(phenoxy)phenylacetic acid derivatives |
| NZ545943A (en) * | 2003-09-19 | 2009-09-25 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| WO2005115384A2 (en) * | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation |
| US7622491B2 (en) * | 2004-08-13 | 2009-11-24 | Metabolex Inc. | Modulators of PPAR and methods of their preparation |
| MY147518A (en) * | 2004-09-15 | 2012-12-31 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| JO3006B1 (ar) * | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| UA120756C2 (uk) * | 2014-03-20 | 2020-02-10 | Сімабей Терапьютікс, Інк. | Лікування внутрішньопечінкових холестатичних захворювань |
| WO2015157697A1 (en) * | 2014-04-11 | 2015-10-15 | Cymabay Therapeutics, Inc. | Treatment of nafld and nash |
-
2009
- 2009-10-14 CN CN200980144827.7A patent/CN102209532B/zh active Active
- 2009-10-14 WO PCT/US2009/060679 patent/WO2010045361A1/en not_active Ceased
- 2009-10-14 ES ES09821200T patent/ES2712052T3/es active Active
- 2009-10-14 KR KR1020117011217A patent/KR20110091680A/ko not_active Ceased
- 2009-10-14 CA CA2740874A patent/CA2740874C/en active Active
- 2009-10-14 EP EP09821200.4A patent/EP2346498B1/en active Active
- 2009-10-14 BR BRPI0920170A patent/BRPI0920170A2/pt not_active Application Discontinuation
- 2009-10-14 JP JP2011532217A patent/JP5694941B2/ja active Active
- 2009-10-14 MX MX2011004077A patent/MX2011004077A/es active IP Right Grant
- 2009-10-15 US US12/579,996 patent/US20100152295A1/en not_active Abandoned
- 2009-10-16 TW TW098135183A patent/TWI491392B/zh active
-
2016
- 2016-01-13 US US14/995,024 patent/US20160324811A1/en not_active Abandoned
-
2018
- 2018-10-31 US US16/176,349 patent/US11007162B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2346498B1 (en) | 2018-12-26 |
| KR20110091680A (ko) | 2011-08-12 |
| WO2010045361A1 (en) | 2010-04-22 |
| BRPI0920170A2 (pt) | 2016-06-21 |
| TW201028141A (en) | 2010-08-01 |
| JP2012505905A (ja) | 2012-03-08 |
| MX2011004077A (es) | 2011-08-17 |
| EP2346498A4 (en) | 2012-08-01 |
| CA2740874C (en) | 2018-02-27 |
| US20160324811A1 (en) | 2016-11-10 |
| CN102209532A (zh) | 2011-10-05 |
| JP5694941B2 (ja) | 2015-04-01 |
| US20190298672A1 (en) | 2019-10-03 |
| CA2740874A1 (en) | 2010-04-22 |
| EP2346498A1 (en) | 2011-07-27 |
| US20100152295A1 (en) | 2010-06-17 |
| US11007162B2 (en) | 2021-05-18 |
| CN102209532B (zh) | 2015-07-22 |
| TWI491392B (zh) | 2015-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2712052T3 (es) | Métodos para reducir partículas de LDL pequeñas y densas | |
| ES2535427T3 (es) | Sales de lisina nuevas de derivados de 4-((fenoxialquil)tio)-fenoxi ácido acético | |
| CN1882533B (zh) | 4-((苯氧基烷基)硫基)-苯氧基乙酸及其类似物 | |
| ES2546202T3 (es) | Ácidos y análogos 4-(tio(fenoxialquil)) - fenoxiacético | |
| NZ553469A (en) | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | |
| HK1159492B (en) | Methods of reducing small, dense ldl particles | |
| HK1159492A (en) | Methods of reducing small, dense ldl particles | |
| HK1122699B (en) | Novel lysine salts of 4-((phenoxyalkyl) thio)-phenoxyacetic acid derivatives |